Drug Profile

DRT 101

Alternative Names: DRT-101

Latest Information Update: 07 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Darnatein
Class Antirheumatics; Bone morphogenetic proteins; Growth factors; Hormones; Recombinant fusion proteins
Mechanism of Action Activin replacements; Bone morphogenetic protein 2 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Osteoarthritis

Most Recent Events

05 May 2025 Darnatein has patent pending for Activin/BMP7 Chimera Protein Technology in the US and European Union(OSR holding SEC filing, December 2024)
22 Apr 2025 Pharmacodynamics data from preclinical trial in Osteoarthritis released by company
09 Apr 2025 Darnatein has patent protection for Activin/BMP7 Chimera Protein Technology in South Korea and China

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com